Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies
S Sarmah, S Baidya, M DeDOI 10.1002/smll.202506812
Read the original ↗Summary
This review surveys lipid nanoparticle composition, ionisable lipid synthesis and strategies to target delivery of fragile RNA therapeutics while addressing tissue selectivity and immune activation.
Purpose: RNA therapeutics require carriers that protect their cargo and improve delivery to the intended tissue.
Approach: A review of lipid nanoparticle composition, nucleic acid applications and targeting approaches rather than a new experimental comparison.
Key findings: The review identifies tissue selectivity, payload capacity and immune activation as priorities in the development of LNPs for mRNA and siRNA delivery. Ionisable lipid chemistry and targeting mechanisms are discussed as design tools.
Interpretation: Precision delivery requires attention to both carrier composition and biological targeting.
Limitations: The review does not establish comparative clinical outcomes for the proposed strategies.
Related articles
RSC pharmaceutics
Orthogonal ensemble and single-particle characterisation of antisense oligonucleotide lipid nanoparticles
Discover nanoLipid nanoparticle-based mRNA delivery system for cancer management
Molecular cancersiRNA-mediated mismatch repair disruption synergizes with oxaliplatin to restore immune surveillance in microsatellite-stable colorectal cancer
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.